Deal Library / Pharma BD Deal Intelligence

Mylan N.V. — Pharma Deals

The Pharma Closeout tracks 5 deals, $49.4B in disclosed deal value, 4 with a post-close Outcome Score for Mylan N.V..

Median Critic Score: 60  ·  Median Outcome Score: 42

Best outcome: Mylan N.V. / Meda AB (53)  ·  Weakest outcome: Mylan N.V. / Novartis AG (TOBI franchise) (38)

All 5 deals

• Mylan N.V. / Meda AB — 2016 · $9.9B · Mixed — partial payoff, real shortfalls.
• Mylan N.V. / Upjohn Inc. (Pfizer) — 2019 · $12.0B · Underwhelmed — fell short of the thesis.
• Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business) — 2016 · $1.0B · Underwhelmed — fell short of the thesis.
• Mylan N.V. / Novartis AG (TOBI franchise) — 2018 · $463M · Underwhelmed — fell short of the thesis.
• Mylan N.V. / Perrigo Company plc — 2015 · $26.0B

← Deal Library  ·  Interactive search  ·  How we score deals